The clock is already ticking—so why are so many commercial market access teams waiting until the patent expires?
In pharma, timing isn’t just a scheduling issue. It’s a pricing strategy, a contracting strategy, and—ultimately—a revenue strategy.
A grow…
Before You Launch: The Freedom-to-Operate (FTO) Checklist That Can Save Your Company From a $100M Surprise
A launch date is a finish line. But in pharma, it’s also a legal deadline.
The most expensive “oops” in drug development isn’t a failed trial—it’…
Most pharma buyers treat Paragraph IV diligence like paperwork. That’s why they keep getting surprised.
Paragraph IV filings are supposed to be a warning system. A signal that a generic (or biosimilar) is challenging a branded drug’s patents—and that t…
Paragraph IV Filings: The Procurement Due Diligence Tool Most Pharma Buyers Ignore Read Post »
Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re a pharma executive, investor, or in-house counsel, you’ve probably heard the same comforting story: “A patent is a patent.” File early, secure…
Most pharma teams treat patent expiry dates like a calendar item.
A date to track. A deadline to monitor. A risk to manage.
But if you’re still thinking of drug patent expiry as a “back-office” timeline, you’re leaving money on the table.
Because the r…
Turn Drug Patent Expiry Dates Into Your Next Sales Campaign Read Post »
Sell the Line—Before the Patent Breaks: A Business Development Playbook for Solid-Dose Equipment Suppliers
The most expensive mistake in pharma equipment sales isn’t pricing. It’s timing.
In solid dose manufacturing, the window between “patent still in…
The impact of Lyrica (pregabalin) on liver function is a topic of concern for individuals taking the medication. Lyrica is… https://www.Drugchatter.com/chat/26609/how-does-lyrica-affect-liver-function/
DrugChatter: How does lyrica affect liver function? Read Post »
The Smarter Monopoly? Orphan Drug Exclusivity vs. Standard Drug Patents
Big Pharma loves a clean narrative: innovation deserves protection, and protection drives investment. But the real question isn’t whether exclusivity exists—it’s how it’s structure…
The Smarter Monopoly: Orphan Drug Exclusivity vs. Standard Drug Patents Read Post »
Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
Biologics don’t just “end.” They cliff. And when Loss of Exclusivity (LOE) hits, the market doesn’t wait for your pipeline to catch up.
Fo…
Patents aren’t just about invention anymore—they’re about timing.
For years, the public conversation around drug pricing has focused on one question: Why do generics take so long to arrive? But the more uncomfortable answer is that, in many cases, th…
Get new actionable insights and updates from BiotechBlog
